Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C1522282 (
EMT
)
2,868
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The lncRNA
AFAP1
-AS1, oriented from an antisense direction to the protein-coding gene
AFAP1
in the opposite strand, was upregulated in a variety of tumors and associated with poor prognosis, including lung cancer, breast cancer, ovarian cancer, and so on. However, the biological role of
AFAP1
-AS1 in clear cell renal cell carcinoma (ccRCC) is still unknown. We observed that
AFAP1
-AS1 expression was significantly upregulated in ccRCC tissues and that patients with high-level expression of
AFAP1
-AS1 had a shorter overall survival. Knockdown of
AFAP1
-AS1 markedly suppressed the progression of proliferation, invasion, migration, and
EMT
in ccRCC cells. Downregulation of
AFAP1
-AS1 resulted in an increase in E-cadherin and a decrease in vimentin. Noticeably, we found that PTEN has a negative correlation with the lncRNA
AFAP1
-AS1 expression. Further studies verified that PTEN deficiency effectively attenuated the ability of
AFAP1
-AS1 in promoting ccRCC cell proliferation, invasion, migration, and
EMT
. Moreover, the similar biological response of silencing
AFAP1
-AS1 was observed in our ccRCC mice model. Knockdown of
AFAP1
-AS1 evidently suppressed tumor growth. Taken together, our results provide the evidences that silencing of
AFAP1
-AS1 inhibits cell proliferation,
EMT
, and metastasis through PTEN-dependent signaling, and our findings elucidate a novel potential therapeutic target or biomarker for the treatment of ccRCC.
...
PMID:Silencing of lncRNA AFAP1-AS1 Inhibits Cell Growth and Metastasis in Clear Cell Renal Cell Carcinoma. 3083 52
